The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Introduction Colorectal cancer is the fourth most common cancer in the UK. There remains a
need for improved risk stratification following curative resection. Circulating-tumour DNA …

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

One of the great challenges in therapeutic oncology is determining who might achieve
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …

Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated
compared with those of healthy controls, but the sources of this extra cfDNA have never …

The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization
and protection or packaging within mononucleosomes, the smallest and the most stabilized …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Background Disulfidptosis is independent of apoptosis, ferroptosis, and cuproptosis and is
associated with cancer progression, treatment response, and prognosis. However, the …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …